North America Cervical Cancer Diagnostic Testing Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Type (PAP Testing, HPV Testing, Colposcopy, Cervical Biopsies, Cystoscopy, and Others) and Service Provider (Diagnostics and Research Laboratories, Hospitals and Clinics, Specialty Clinics, and Home Care Services)
Market Introduction
The North America Cervical Cancer Diagnostic Testing Market has been segmented into the US, Canada, and Mexico. The US held the largest share of the North America Cervical Cancer Diagnostic Testing Market in 2021. In North America, the US holds a significant share of the Cervical Cancer Diagnostic Testing market. The growth of the market in the country is primarily driven by a vast number of R&D activities; financial aids by governments, other private and non-private organizations; collaborations within pharmaceuticals and technology companies; and increasing prevalence of neurological diseases in the country. Additionally, increasing the active participation of the government organizations in enhancing the testing procedures is expected to boost the market during the forecast period. Furthermore, the implementation of regulatory policies for rare diseases is likely to offer a significant opportunity for the market's growth during the forecast period. For instance, the American Cancer Society (ACS) in September 2020 updated the guidelines for cervical cancer screening. Thus, such active involvement organization is expected to support the market growth. Moreover, as per the World Health Organization - Cervical Cancer Country Profiles, 2021, the age-standardized cervical cancer incidence rate per 100 000 women in 2020 is estimated to be 6.2. The US health system is witnessing a massive number of product innovations for the testing of chronic conditions and rare diseases, which would, in turn, drive the growth of the market in the US during the forecast period.
In case of COVID-19, North America is highly affected the US. The chaotic situation was created in the medical industry across the countries, increased demand for diagnosing and therapeutic devices have dramatically increased in the hospitals. For instance, the demand for ventilators, respirators, and in vitro diagnostic (IVD) tests has risen drastically in hospitals across the countries in the region. The FDA has increased its efforts to support the health of people and has imposed several guidelines and for hospitals and medical device companies. Various companies also enhanced their research and development activities for diagnostics tests and therapeutic devices. Due to the fear of infection of COVID19, women are hesitating to take cervical cancer testing such as the PAP test, biopsies, colonoscopy, and others, as it generally requires an actual visit to the healthcare. This trend among the patients is expected to affect the cervical cancer diagnostic testing market in the region. However, healthcare providers are now offering at-home testing services for the initial diagnosis through point-of-care devices and kits. The market players are actively involved in organic and inorganic developments. Thus, the outbreak of COVID-19 has shown a remarkable impact on market growth in the region.
Get more information on this report :
Market Overview and Dynamics
The North America cervical cancer diagnostic testing market is expected to grow from US$ 2,250.53 million in 2021 to US$ 3,159.09 million by 2028; it is estimated to grow at a CAGR of 5.0% from 2021 to 2028. Healthcare players concentrate on several countries, owing to the large population suffering from cancer in these countries. Moreover, with rising production costs against their practices, these companies strive to produce sufficient revenue to entertain their investors. Having presence in growing countries offers reliable and profitable growth opportunities to the major players to lower their operating costs and expand their geographic reach. Advancements in biotechnology have increased the demand for improved diagnostics based on analytical systems in the healthcare market in several countries; they are also easing the shift toward point of care diagnostics kits. Fields such as infectious disease testing, molecular oncology, and pharmacogenomics in several countries open new growth avenues. Hence, healthcare companies are targeting patients or consumers from several economies. Companies in the healthcare sector have been investing significant amounts of their revenue in R&D activities to develop better and advanced offerings and technologies. Several countries across the region are going at a good rate. Several activities in the region propel the demand for metabolomics-related services. Thus, the rising prevalence of cancer and technological advancements in several economies are boosting the cervical cancer diagnosis test market and providing significant growth opportunities to the players operating in the North America market.
Key Market Segments
In terms of type, the PAP testing segment accounted for the largest share of the North America cervical cancer diagnostic testing market in 2020. In terms of service provider, the diagnostics and research laboratories segment held a larger market share of the North America cervical cancer diagnostic testing market in 2020.
Major Sources and Companies Listed
A few major primary and secondary sources referred to for preparing this report on the North America cervical cancer diagnostic testing market are company websites, annual reports, financial reports, national government documents, and statistical database, among others. Major companies listed in the report are Abbott; BD; Cooper Companies, Inc.; DYSIS Medical Inc; F. Hoffmann-La Roche Ltd.; Femasys Inc.; Guided Therapeutics, Inc; Hologic, Inc.; QIAGEN; and Quest Diagnostics Incorporated among others.
Reasons to buy report
- To understand the North America cervical cancer diagnostic testing market landscape and identify market segments that are most likely to guarantee a strong return
- Stay ahead of the race by comprehending the ever-changing competitive landscape for North America cervical cancer diagnostic testing market
- Efficiently plan M&A and partnership deals in North America cervical cancer diagnostic testing market by identifying market segments with the most promising probable sales
- Helps to take knowledgeable business decisions from perceptive and comprehensive analysis of market performance of various segment form North America cervical cancer diagnostic testing market
- Obtain market revenue forecast for market by various segments from 2021-2028 in North America region.
North America Cervical Cancer Diagnostic Testing Market Segmentation
North America Cervical Cancer Diagnostic Testing Market - By Type
- PAP Testing
- HPV Testing
- Colposcopy
- Cervical Biopsies
- Cystoscopy
- Others
North America Cervical Cancer Diagnostic Testing Market - By Service Provider
- Diagnostics and Research Laboratories
- Hospitals and Clinics
- Specialty Clinics
- Home Care Services
North America Cervical Cancer Diagnostic Testing Market - By Country
- US
- Canada
- Mexico
North America Cervical Cancer Diagnostic Testing Market - Company Profiles
- Abbott
- BD
- Cooper Companies, Inc.
- DYSIS Medical Inc
- F. Hoffmann-La Roche Ltd.
- Femasys Inc.
- Guided Therapeutics, Inc
- Hologic, Inc.
- QIAGEN
- Quest Diagnostics Incorporated
1. Introduction
1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
1.3.1 North America Cervical Cancer Diagnostic Testing Market – By Type
1.3.2 North America Cervical Cancer Diagnostic Testing Market – By Service Provider
1.3.3 North America Cervical Cancer Diagnostic Testing Market – By Country
2. Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. North America Cervical Cancer Diagnostic Testing Market – Market Landscape
4.1 Overview
4.2 North America PEST Analysis
4.3 Experts Opinion
5. North America Cervical Cancer Diagnostic Testing Market – Key Market Dynamics
5.1 Market Drivers
5.1.1 Growing Prevalence of Cervical Cancer
5.1.2 Rising HPV Infections
5.2 Market Restraints
5.2.1 Dearth of Awareness about the Diagnosis and Treatment Methods
5.3 Market Opportunities
5.3.1 Development Opportunities in Several Countries
5.4 Future Trends
5.4.1 Growing Development and Launch of Innovative Products
5.5 Impact Analysis
6. Cervical Cancer Diagnostic Testing Market– North America Analysis
6.1 North America Cervical Cancer Diagnostic Testing Market Revenue Forecast and Analysis
7. North America Cervical Cancer Diagnostic Testing Market Analysis – By Type
7.1 Overview
7.2 North America Cervical Cancer Diagnostic Testing Market, By Type, 2021 & 2028 (%)
7.3 PAP Testing
7.3.1 Overview
7.3.2 PAP Testing: Cervical Cancer Diagnostic Testing Market Revenue and Forecasts to 2028 (US$ Million)
7.4 HPV Testing
7.4.1 Overview
7.4.2 HPV Testing: Cervical Cancer Diagnostic Testing Market Revenue and Forecasts to 2028 (US$ Million)
7.5 Colposcopy
7.5.1 Overview
7.5.2 Colposcopy: Cervical Cancer Diagnostic Testing Market Revenue and Forecasts to 2028 (US$ Million)
7.6 Cervical Biopsies
7.6.1 Overview
7.6.2 Cervical Biopsies: Cervical Cancer Diagnostic Testing Market Revenue and Forecasts to 2028 (US$ Million)
7.7 Cystoscopy
7.7.1 Overview
7.7.2 Cystoscopy: Cervical Cancer Diagnostic Testing Market Revenue and Forecasts to 2028 (US$ Million)
7.8 Others
7.8.1 Overview
7.8.2 Others: Cervical Cancer Diagnostic Testing Market Revenue and Forecasts to 2028 (US$ Million)
8. North America Cervical Cancer Diagnostic Testing Market Analysis – By Service Provider
8.1 Overview
8.2 North America Cervical Cancer Diagnostic Testing Market Share by Service Provider - 2021 & 2028 (%)
8.3 Diagnostics and Research Laboratories
8.3.1 Overview
8.3.2 Diagnostic Laboratories and Research Laboratories: Cervical Cancer Diagnostic Testing Market Revenue and Forecast to 2028 (US$ Million)
8.4 Hospitals and Clinics
8.4.1 Overview
8.4.2 Hospitals and Clinics: Cervical Cancer Diagnostic Testing Market Revenue and Forecast to 2028 (US$ Million)
8.5 Specialty Clinics
8.5.1 Overview
8.5.2 Specialty Clinics: Cervical Cancer Diagnostic Testing Market Revenue and Forecast to 2028 (US$ Million)
8.6 Home Care services
8.6.1 Overview
8.6.2 Home Care Services: Cervical Cancer Diagnostic Testing Market Revenue and Forecast to 2028 (US$ Million)
9. North America Cervical Cancer Diagnostic Testing Market – Country Analysis
9.1 North America: Cervical Cancer Diagnostic Testing Market
9.1.1 Overview
9.1.3 North America: Cervical Cancer Diagnostic Testing Market, by Country, 2021 & 2028 (%)
9.1.3.1 US: Cervical Cancer Diagnostic Testing Market – Revenue and Forecast to 2028 (US$ Million)
9.1.3.1.1 Overview
9.1.3.1.2 US: Cervical Cancer Diagnostic Testing Market – Revenue and Forecast to 2028 (US$ Million)
9.1.3.1.3 US: Cervical Cancer Diagnostic Testing Market, by Type, 2019–2028 (US$ Million)
9.1.3.1.4 US: Cervical Cancer Diagnostic Testing Market, by Service Provider, 2019–2028 (US$ Million)
9.1.3.2 Canada: Cervical Cancer Diagnostic Testing Market – Revenue and Forecast to 2028 (US$ Million)
9.1.3.2.1 Overview
9.1.3.2.2 Canada: Cervical Cancer Diagnostic Testing Market – Revenue and Forecast to 2028 (US$ Million)
9.1.3.2.3 Canada: Cervical Cancer Diagnostic Testing Market, by Type, 2019–2028 (US$ Million)
9.1.3.2.4 Canada: Cervical Cancer Diagnostic Testing Market, by Service Provider, 2019–2028 (US$ Million)
9.1.3.3 Mexico: Cervical Cancer Diagnostic Testing Market – Revenue and Forecast to 2028 (US$ Million)
9.1.3.3.1 Overview
9.1.3.3.2 Mexico: Cervical Cancer Diagnostic Testing Market – Revenue and Forecast to 2028 (US$ Million)
9.1.3.3.3 Mexico: Cervical Cancer Diagnostic Testing Market, by Type, 2019–2028 (US$ Million)
9.1.3.3.4 Mexico: Cervical Cancer Diagnostic Testing Market, by Service Provider, 2019–2028 (US$ Million)
10. Impact Of COVID-19 Pandemic on North America Cervical Cancer Diagnostic Testing Market
10.1 North America: Impact Assessment of COVID-19 Pandemic
11. Cervical Cancer Diagnostic Testing Market–Industry Landscape
11.1 Overview
11.2 Organic Developments
11.2.1 Overview
11.3 Inorganic Developments
11.3.1 Overview
12. Company Profiles
12.1 F. Hoffmann-La Roche Ltd.
12.1.1 Key Facts
12.1.2 Business Description
12.1.3 Products and Services
12.1.4 Financial Overview
12.1.5 SWOT Analysis
12.1.6 Key Developments
12.2 Abbott
12.2.1 Key Facts
12.2.2 Business Description
12.2.3 Products and Services
12.2.4 Financial Overview
12.2.5 SWOT Analysis
12.2.6 Key Developments
12.3 Quest Diagnostics Incorporated
12.3.1 Key Facts
12.3.2 Business Description
12.3.3 Products and Services
12.3.4 Financial Overview
12.3.5 SWOT Analysis
12.3.6 Key Developments
12.4 QIAGEN
12.4.1 Key Facts
12.4.2 Business Description
12.4.3 Products and Services
12.4.4 Financial Overview
12.4.5 SWOT Analysis
12.4.6 Key Developments
12.5 Hologic, Inc.
12.5.1 Key Facts
12.5.2 Business Description
12.5.3 Products and Services
12.5.4 Financial Overview
12.5.5 SWOT Analysis
12.5.6 Key Developments
12.6 DYSIS Medical Inc
12.6.1 Key Facts
12.6.2 Business Description
12.6.3 Products and Services
12.6.4 Financial Overview
12.6.5 SWOT Analysis
12.6.6 Key Developments
12.7 Femasys Inc.
12.7.1 Key Facts
12.7.2 Business Description
12.7.3 Products and Services
12.7.4 Financial Overview
12.7.5 SWOT Analysis
12.7.6 Key Developments
12.8 Guided Therapeutics, Inc
12.8.1 Key Facts
12.8.2 Business Description
12.8.3 Products and Services
12.8.4 Financial Overview
12.8.5 SWOT Analysis
12.8.6 Key Developments
12.9 Cooper Companies, Inc.
12.9.1 Key Facts
12.9.2 Business Description
12.9.3 Products and Services
12.9.4 Financial Overview
12.9.5 SWOT Analysis
12.9.6 Key Developments
12.10 BD
12.10.1 Key Facts
12.10.2 Business Description
12.10.3 Products and Services
12.10.4 Financial Overview
12.10.5 SWOT Analysis
12.10.6 Key Developments
13. Appendix
13.1 About The Insight Partners
13.2 Glossary of Terms
LIST OF TABLES
Table 1. North America Cervical Cancer Diagnostic Testing Market – Revenue and Forecast to 2028 (US$ Million)
Table 2. US Cervical Cancer Diagnostic Testing Market, by Type – Revenue and Forecast to 2028 (US$ Million)
Table 3. US: Cervical Cancer Diagnostic Testing Market, by Service Provider– Revenue and Forecast to 2028 (US$ Million)
Table 4. Canada: Cervical Cancer Diagnostic Testing Market, by Type – Revenue and Forecast to 2028 (US$ Million)
Table 5. Canada Cervical Cancer Diagnostic Testing Market, by Service Provider– Revenue and Forecast to 2028 (US$ Million)
Table 6. Mexico: Cervical Cancer Diagnostic Testing Market, by Type – Revenue and Forecast to 2028 (US$ Million)
Table 7. Mexico Cervical Cancer Diagnostic Testing Market, by Service Provider– Revenue and Forecast to 2028 (US$ Million)
Table 8. Organic Developments
Table 9. Inorganic Developments
Table 10. Glossary of Terms
LIST OF FIGURES
Figure 1. North America Cervical Cancer Diagnostic Testing Market Segmentation
Figure 2. North America Cervical Cancer Diagnostic Testing Market, By Country
Figure 3. North America Cervical Cancer Diagnostic Testing Market Overview
Figure 4. PAP Testing Segment Held Largest Share of the Market in 2021
Figure 5. The US is Expected to Show Remarkable Growth During the Forecast Period
Figure 6. North America: PEST Analysis
Figure 7. Experts Opinion
Figure 8. Impact Analysis of Drivers and Restraints Pertaining to North America Cervical Cancer Diagnostic Testing Market
Figure 9. North America Cervical Cancer Diagnostic Testing Market Forecast to 2028
Figure 10. North America Cervical Cancer Diagnostic Testing Market, by Type, 2021 & 2028 (%)
Figure 11. North America Pap Testing: Cervical Cancer Diagnostic Testing Market Revenue and Forecasts to 2028 (US$ Million)
Figure 12. North America HPV Testing: Cervical Cancer Diagnostic Testing Market Revenue and Forecasts to 2028 (US$ Million)
Figure 13. North America Colposcopy: Cervical Cancer Diagnostic Testing Market Revenue and Forecasts to 2028 (US$ Million)
Figure 14. North America Cervical Biopsies: Cervical Cancer Diagnostic Testing Market Revenue and Forecasts to 2028 (US$ Million)
Figure 15. North America Cystoscopy: Cervical Cancer Diagnostic Testing Market Revenue and Forecasts to 2028 (US$ Million)
Figure 16. North America Others: Cervical Cancer Diagnostic Testing Market Revenue and Forecasts to 2028 (US$ Million)
Figure 17. North America Cervical Cancer Diagnostic Testing Market Share by Service Provider - 2021 & 2028 (%)
Figure 18. North America Diagnostic Laboratories and Research Laboratories: Cervical Cancer Diagnostic Testing Market Revenue and Forecasts To 2028 (US$ Million)
Figure 19. North America Hospitals and Clinics: Cervical Cancer Diagnostic Testing Market Revenue and Forecasts To 2028 (US$ Million)
Figure 20. North America Specialty Clinics: Cervical Cancer Diagnostic Testing Market Revenue and Forecasts To 2028 (US$ Million)
Figure 21. North America Home Care Services: Cervical Cancer Diagnostic Testing Market Revenue and Forecasts To 2028 (US$ Million)
Figure 22. North America: Cervical Cancer Diagnostic Testing Market, by Key Country – Revenue (2021) (US$ Million)
Figure 23. North America: Cervical Cancer Diagnostic Testing Market, by Country, 2021 & 2028 (%)
Figure 24. US: Cervical Cancer Diagnostic Testing Market – Revenue and Forecast to 2028 (US$ Million)
Figure 25. Canada: Cervical Cancer Diagnostic Testing Market – Revenue and Forecast to 2028 (US$ Million)
Figure 26. Mexico: Cervical Cancer Diagnostic Testing Market – Revenue and Forecast to 2028 (US$ Million)
Figure 27. Impact of COVID-19 Pandemic in North American Country Markets
- Abbott
- BD
- Cooper Companies, Inc.
- DYSIS Medical Inc
- F. Hoffmann-La Roche Ltd.
- Femasys Inc.
- Guided Therapeutics, Inc
- Hologic, Inc.
- QIAGEN
- Quest Diagnostics Incorporated
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the North America cervical cancer diagnostic testing market.
- Highlights key business priorities in order to assist companies to realign their business strategies
- The key findings and recommendations highlight crucial progressive industry trends in the North America cervical cancer diagnostic testing market, thereby allowing players across the value chain to develop effective long-term strategies
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
- Scrutinize in-depth North America market trends and outlook coupled with the factors driving the cervical cancer diagnostic testing market, as well as those hindering it
- Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution